0000000001090997
AUTHOR
A. Butera
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
Abstract Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-bas…
SOLVENTI ORGANICI COME FATTORI DI RISCHIO PER LE MALATTIE AUTOIMMUNI: RIVALUTAZIONE A DIECI ANNI DI ANA E COMPLEMENTEMIA IN OPERATORI AFFERENTI AI LABORATORI DEL DIPARTIMENTO STEBICEF DELL’UNIVERSITÀ DEGLI STUDI DI PALERMO
solventi, ANA, complementemia